TITLE

Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation

AUTHOR(S)
Bihl, Florian; Russmann, Stefan; Gurtner, Vanina; Di Giammarino, Loriana; Pizzi-Bosman, Loredana; Michel, Martine; Cerny, Andreas; Hadengue, Antoine; Majno, Pietro; Giostra, Emiliano; Castelli, Damiano; Mentha, Gilles
PUB. DATE
January 2010
SOURCE
BMC Gastroenterology;2010, Vol. 10, p71
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Hepatitis B immune globulins (HBIG) in combination with nucleos(t)ide analogues (NA) are effectively used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, associated treatment costs for HBIG are exceedingly high. Methods: Fresh frozen plasma obtained from blood donors with high anti-HBs levels (hyperimmune plasma, HIP) containing at least 4,500 IU anti-HBs was used as alternative treatment for HBV recurrence prophylaxis post-LT. Results: Twenty-one HBV-related LT recipients received HIP starting at transplantation, followed by long-term combination treatment with NA. Mean follow-up time was 4.5 years (range 0.5-12.6) and each patient received on average 8.2 HIP per year (range 5.8-11.4). Anti-HBs terminal elimination kinetic after HIP administration was 20.6 days (range 13.8-30.9), which is comparable to values reported for commercial HBIG products. All 21 patients remained free of HBV recurrence during follow-up and no transfusion-transmitted infection or other serious complication was observed. Seven patients developed reversible mild transfusion reactions. The cost for one HIP unit was US$140; average yearly HBIG treatment cost was US$1,148 per patient, as compared to US$25,000-100,000 for treatment with commercial HBIG. Conclusion: The results of this study suggest that the use of HIP may be a useful and economical approach for the prevention of HBV recurrence post-LT if used in combination with NA. Additional prospective controlled studies in larger populations are needed to confirm these results.
ACCESSION #
52798291

 

Related Articles

  • Hepatitis B Immunoglobulin Prophylaxis after Liver Transplantation: Experience in a Tertiary Transplant Centre. Varghese, Joy; Sachan, Deepti; Reddy, Mettu S.; Cherian, Tom; Jothimani, Dinesh; Venugopal, Kota; Arikichenin, Olithselvan; Perumalla, Rajasekar; Narasimhan, Gomathy; Shanmugam, Vivekananthan; Srinivasan Vijaya; Jayanthi Venkataraman; Rela, Mohamed // Experimental & Clinical Hepatology;Aug2014, Vol. 4 Issue 3, p1 

    Background: Prophylaxis with hepatitis B immunoglobulin (HBIG) and nucleoside analogs can prevent Hepatitis B virus (HBV) recurrence after liver transplant (LT). Aim: To determine the efficacy and cost of maintaining immunoprophylaxis with HBIG and hyperimmune plasma (HIP) for 6 months after LT....

  • Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation. Khemichian, Saro; Hsieh, Mary; Zhang, Shi-Rong; Limurti, Joyce; Kim, John; Fong, Tse-Ling // Digestive Diseases & Sciences;Sep2015, Vol. 60 Issue 9, p2807 

    Background: Hepatitis B immune globulin (HBIg) in combination with a nucleos(t)ide analog is the mainstay of prophylactic regimen to prevent recurrence of hepatitis B following orthotopic liver transplantation (OLT). HBIg therapy is costly and inconvenient for the patients. There is a growing...

  • Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B. Fung, James; Chan, See-Ching; Cheung, Cindy; Yuen, Man-Fung; Chok, Kenneth Siu-Ho; Sharr, William; Chan, Albert Chi-Yan; Cheung, Tan-To; Seto, Wai-Kay; Fan, Sheung-Tat; Lai, Ching-Lung; Lo, Chung-Mau // American Journal of Gastroenterology;Jun2013, Vol. 108 Issue 6, p942 

    OBJECTIVES:The long-term outcomes of oral antiviral therapy without hepatitis B immune globulin (HBIG) in prevention of reinfection with hepatitis B after liver transplantation are not known. We aimed to determine the long-term outcomes from a large population of chronic hepatitis B (CHB) liver...

  • Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination Marugán, R. Bárcena; Garcıa-Hoz, F.; Vázquez Romero, M.; Nash, R.; Mateos, M.; González Alonso, R.; González, M. Garcıa; Plaza, A. Garcıa // American Journal of Gastroenterology;Sep2002, Vol. 97 Issue 9, p2398 

    OBJECTIVES:To assess de novo hepatitis B virus (HBV) transmission from liver donors with HBV serum markers (HBM) to their recipients and the need for HBV vaccination before liver transplantation.METHODS:A total of 108 orthotopic liver transplantations for nonviral disease and the risk of...

  • Hepatitis B Immune Globulin in Liver Transplantation Prophylaxis: An Update. Dindoost, Payam; Mohammad Jazayeri, Seyed; Moayed Alavian, Seyed // Hepatitis Monthly;Mar2012, Vol. 12 Issue 3, p168 

    Context: Liver transplantation is the best treatment option for end-stage liver disease following hepatitis B (HBV) infection. However, the high rate of recurrence of HBV infection following transplantation is a disadvantage of this option. Evidence Acquisition: Over the past 2 decades, the gold...

  • Prevention of Fungal and Hepatitis Virus Infections in Liver Transplantation. Paya, Carlos V. // Clinical Infectious Diseases;7/1/2001 Supplement 1, Vol. 33, pS47 

    Discusses invasive fungal infections and the recurrence of hepatitis B virus and hepatitis C virus infections in orthotopic liver transplant recipients. Risk factors for fungal infections; Background and epidemiology of Candida species infection; Preventive measures.

  • The significance of heparin-coated veno-venous bypass circuits in liver transplantation. Scholz, Tim; Solberg, Rigmor; Okkenhaug, Cecilie; Videm, Vibeke; Gallimore, Michael J; Mathisen, Øystein; Mollnes, Tom E; Bergan, Anstein; Søreide, Odd; Klintman, Göran B; Aasen, Ansgar O // Perfusion;Jan2002, Vol. 17 Issue 1, p45 

    We studied the effects of veno-venous bypass (VVBP) circuit surface heparinization on the activation of the plasma defence systems (coagulation, fibrinolysis, kallikrein- kinin and complement) and leukocyte activation in a prospective randomized study in 20 patients during and 1 day after liver...

  • Seroprevalence of Hepatitis B virus infection among blood donors in Shia Muslims in a population of Lucknow. Ahmed, S.; Chaturvedi, H.; Mehdi, S. R. // Bangladesh Journal of Medical Science;Apr2013, Vol. 12 Issue 2, p146 

    Background: The objective of this study was to determine the prevalence and trends in hepatitis B infection among blood donors Shia Muslims attending the blood bank in Era's Lucknow Medical College lucknow. A retrospective study was carried out by reviewing the results of HBsAg among blood...

  • Hepatitis B virus subgenotype A1, occurrence of subgenotype D4, and S gene mutations among voluntary blood donors in Kenya. Kwange, Simeon Owuor; Budambula, Nancy L. M.; Kiptoo, Michael Kibet; Okoth, Fredrick; Ochwoto, Missiani; Oduor, Margaret; Kimotho, James Hungo // Virus Genes;Dec2013, Vol. 47 Issue 3, p448 

    Kenya is one of the high endemic zones for hepatitis B virus (HBV) infection. The consensuses on prevalence of the HBV genotypes and the existence of their variants have not been fully established in Kenya. Hence, there is a need to further monitor the diversity of HBV. This study aimed to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics